LOGIN
WCO-IOF 2016: Odanacatib has a significant effect on volumetric BMD versus placebo
May 2016
WCO-IOF 2016: Odanacatib has a significant effect on volumetric BMD versus placebo
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Effect of odanacatib on bone mineral density and estimated bone strength in postmenopausal women: a CT-based substudy of the phase 3 long-term odanacatib fracture trial (LOFT)
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
A subset of 164 women from the Long-Term Odanacatib Fracture Trial were included in this imaging sub-study to evaluate the effect of odanacatib versus placebo on volumetric bone mineral density (vBMD) of the lumbar spine and total hip. Follow-up was made at 24 months of treatment, and percent change in trabecular vBMD of the lumbar spine and cortical vBMD of total hip were compared. Results demons...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.